| Â | UAE | eGFR |
|---|
OR (95% CI) | p values | OR (95% CI) | p values |
|---|
Plaques |
 Model 1 | 1.22 (1.11–1.35) |  < 0.001 | 0.49 (0.44–0.54) |  < 0.001 |
 Model 2 | 1.16 (1.03–1.30) | 0.017 | 0.90 (0.79–1.02) | 0.098 |
 Model 3 | 1.19 (1.05–1.35) | 0.007 | 0.88 (0.77–1.01) | 0.059 |
 Model 4 | 1.15 (1.00–1.32) | 0.046 | 0.88 (0.76–1.02) | 0.079 |
 Model 5 | 1.20 (1.03–1.39) | 0.020 | 0.88 (0.75–1.02) | 0.089 |
Stenosis |
 Model 1 | 1.30 (1.17–1.45) |  < 0.001 | 0.61 (0.54–0.68) |  < 0.001 |
 Model 2 | 1.27 (1.13–1.43) |  < 0.001 | 1.04 (0.91–1.18) | 0.614 |
 Model 3 | 1.26 (1.11–1.42) |  < 0.001 | 1.04 (0.91–1.19) | 0.593 |
 Model 4 | 1.22 (1.07–1.39) | 0.003 | 1.08 (0.93–1.25) | 0.312 |
 Model 5 | 1.17 (1.01–1.35) | 0.036 | 1.12 (0.95–1.31) | 0.177 |
- UAE urinary albumin excretion, eGFR estimated glomerular filtration rate, DD duration of diabetes, APA anti-platelet agents, LLD lipid-lowering drugs, AHA anti-hypertensive agents, SBP systolic blood pressure, DBP diastolic blood pressure, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose, HbA1c glycated hemoglobin A1c, FCP fasting C-peptide, 2-h PCP 2-h postprandial C-peptide, HOMA2-IR HOMA of insulin resistance, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine transaminase, SUA serum uric acid
- Model 1: unadjusted
- Model 2: Adjusted for age, sex, DD, hypertension, smoking status and alcohol use
- Model 3: Further adjustment for use of AHA, LLD, APA
- Model 4: Further adjustment for SBP, DBP, BMI, WC and WHR
- Model 5: Further adjustment for ALT, TG, TC, HDL-C, LDL-C, SUA, FPG, 2-h PPG, HbA1c, FCP, 2-h PCP, HOMA2-IR
